Metrics to compare | GENF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGENFPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.7x | −5.1x | −0.4x | |
PEG Ratio | −0.26 | −0.02 | 0.00 | |
Price/Book | −19.8x | 2.4x | 2.6x | |
Price / LTM Sales | 18.7x | 8.3x | 3.0x | |
Upside (Analyst Target) | - | 173.7% | 54.2% | |
Fair Value Upside | Unlock | −9.3% | 6.4% | Unlock |
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005 for the treatment of mitochondrial dysfunction and sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company was founded in 2020 and is headquartered in London, the United Kingdom.